Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the efficacy and safety of topical p-menthane-3,8-diol (PMD)-rich Corymbia Citriodora oil (Citriodiol®) in children with impetigo. Citriodiol® is already known to be effective as an insect repellent and is safe in its topical application. The investigators have also found in our laboratory that it is bactericidal against Staphylococcus aureus, the bacteria responsible for causing impetigo. Parents are always searching for a natural alternative to antibiotics (the current gold standard treatment for impetigo), and the investigators believe Citriodiol® could provide this possible alternative.


Clinical Trial Description

The extract of lemon eucalyptus, a common plant, has since the 1970s been used in commercial insect repellent products. Recently, it has been shown that lemon eucalyptus has potent anti-bacterial and anti-fungal effects that should assist in the treatment of inflammatory conditions such as impetigo. Our aim is to investigate this further by investigating the safety and efficacy of this product in the treatment of Impetigo.

A randomised, double-blinded, three-armed pilot study, involving a total of 30 patients will be recruited from the dermatology outpatient department clinic at Royal North Shore hospital for this study. These patients will be between the ages of 12 months and 12 years with a clinical diagnosis of Impetigo.

The three treatment groups will include a 2% or 5% topical p-menthane-3,8-diol (extracted from lemon eucalyptus) and a topical Mupirocin arm, which will be applied topically twice a day till resolution of symptoms. Follow-up will occur weekly until resolution of symptoms, which is expected within 2 weeks. Photographs, disease severity assessment and lesional swabs for culture will be taken at recruitment and as progress. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01611909
Study type Interventional
Source Royal North Shore Hospital
Contact Shreya Dixit, B Med Sci, MBBS (Hons)
Phone (02) 9926 7111
Email rnsdermresearch@gmail.com
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date July 2012
Completion date March 2013

See also
  Status Clinical Trial Phase
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT01153828 - EU PV for Retapamulin-Prescribing N/A
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Terminated NCT00986856 - Fucidin® Cream in the Treatment of Impetigo Phase 4
Completed NCT01397461 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Phase 3
Recruiting NCT02090764 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Phase 3
Completed NCT02775617 - Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Phase 4
Completed NCT03177993 - Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji N/A
Completed NCT03429595 - Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo Phase 2
Completed NCT04287777 - Safety and Efficacy of Mupirocin Gel in Children With Impetigo Phase 3
Completed NCT00626795 - Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) Phase 2
Completed NCT00758862 - The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo Phase 2
Recruiting NCT01943136 - The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Phase 1
Completed NCT01670032 - Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo Phase 2/Phase 3
Completed NCT01171326 - Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients Phase 2
Completed NCT01367314 - Safety and Efficacy of Topical NVC-422 Gel in Impetigo Phase 2
Completed NCT01126268 - Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Phase 4
Completed NCT00852540 - Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA Phase 3
Completed NCT00133848 - Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment Phase 3